Obesity associated with longer survival for men with metastatic melanoma
Unexpected result launches search for underlying cause, including hormonal impact
MD Anderson News Release February 12, 2018
Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report in a study published in Lancet Oncology of 1,918 patients in six independent clinical cohorts.
This effect, referred to as the “Obesity Paradox”, principally manifested itself in men, said Jennifer McQuade, M.D., lead author and instructor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.
“Obese men consistently did much better than men with a normal BMI, with nearly a doubling of overall survival,” McQuade said. The researchers found no significant differences in survival between women with normal, overweight or obese BMI.
“The question is what underlying mechanism causes this advantage in obese men, and can we take advantage of it to improve outcomes in patients with melanoma?” McQuade said. “One hint may be the interaction between obesity, sex, and outcomes, which has not been detected before in any cancer.”
Women with metastatic melanoma have long been known to have better outcomes compared to men, McQuade noted. In this study obesity overcame that survival disadvantage for men, leading researchers to now look at the possible impact of sex hormones in this effect.
Associations don’t prove causation, the researcher’s note, but point to new areas to study in greater depth.
“The public health message is not that obesity is good. Obesity is a proven risk factor for many diseases,” McQuade said. “Even within our metastatic melanoma population, we would not suggest that patients intentionally gain weight. We need to figure out what is driving this paradox and learn how to use this information to benefit all of our patients.”
Obesity is a known risk factor for developing 13 types of cancer according to the World Health Organization and is set to overtake smoking as the leading preventable cause of cancer. The relationship between obesity and survival in patients that already have cancer is not as consistent. Recent studies have shown a similar survival benefit for obese patients with colorectal or kidney cancer.
Obesity expected to be disadvantage
The team expected to find obesity to be harmful for melanoma patients, based in part on research that implicates obesity in activation of a cancer-promoting molecular pathway called IGF-1/PI3K/AKT.
They analyzed the association between body mass index (weight divided by height) and progression-free survival (PFS) and overall survival (OS) in six independent cohorts of patients treated with targeted therapy, immunotherapy or chemotherapy in pivotal trials that led to FDA approval of these drugs.
While advantages in PFS and OS emerged in an overall meta-analysis of the entire group, the survival benefit associated with obesity was restricted to men treated with targeted or immunotherapies, where obese men had a 47 percent decreased risk of death compared to men with normal BMI.
Doubling of overall survival in men
Results from 599 patients receiving combination targeted therapy of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) were:
· Normal BMI of 18.5-24.9 – median PFS of 9.6 months, OS of 19.8 months
· Obese BMI 30 and above – median PFS 15.7 months, OS 33.0 months
A multivariable analysis that included factors such as age, sex, stage, disease burden, certain mutations and prior treatment showed that obesity still improved PFS and OS compared to normal BMI patients.
The team analyzed results by sex and found significant differences only among men.
· Normal BMI men – PFS 7.2 months, OS 16.0 months
· Obese men – PFS 12.8 months, OS 36.5 months.
By contrast, women, for example, had overall median survival of at least 33 months, regardless of BMI. A validation cohort of 240 patients treated with vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor) yielded similar results.
For immunotherapy, in a cohort (330 patients) treated with checkpoint inhibitors blocking either the PD1 check point on T cells or its PD-L1 ligand, results again showed no differences among women, but:
· Normal BMI men – PFS 2.7 months, OS 14.3 months
· Obese men – PFS 7.6 months, OS 26.9 months
A cohort of patients treated with the immune checkpoint inhibitor ipilimumab (207 patients) showed similar results. There was no effect of obesity found among two cohorts (541 patients) treated only with the chemotherapy dacarbazine.
Possible estrogen connection
The researchers are following up to understand biological factors that might provide an advantage to obese male patients. Obesity is associated with increased inflammation, which could improve the effectiveness of checkpoint blockade drugs that unleash an immune response against cancer.
The sex-specificity of the observed differences points to a potential hormonal mediator. Fat (adipose) tissue produces an enzyme called aromatase that converts male hormones called androgens into estrogens, female hormones. Perhaps this happens enough in obese men to help them clear some type of hurdle toward greater survival, McQuade said. The researchers are collaborating with investigators at the University of Pennsylvania that have found that turning on a very specific type of estrogen receptor on melanoma makes it vulnerable to immunotherapy.
The MD Anderson team also is looking at gene expression, mutations and immune profiling to identify potential differences in melanoma in obese and non-obese patients and developing preclinical models.
Co-authors with McQuade and senior author and co-corresponding author Michael Davies, M.D., Ph.D, are Patrick Hwu, M.D., of Melanoma Medical Oncology; Carrie Daniel-MacDougall, Ph.D., of Epidemiology; Kenneth Hess, Ph.D., of Biostatistics; Lauren Haydu, Ph.D., Shenying Fang, M.D., Ph.D., Jennifer Wargo, M.D., Jeffrey Gershenwald, M.D., and Jeffery Lee, M.D., of Surgical Oncology; Christine Spencer of Genomic Medicine; and Meredith McKean, M.D., of Cancer Medicine, all of MD Anderson; and Carmen Mak, Ph.D., Stephen Lane, Dung-Yang Lee, Ph.D., Mathilde Kaper, Tomas Haas, and Jeffery Legos, Ph.D., of Novartis Pharmaceuticals of East Hanover, N.J.; Daniel Wang, M.D., Kathryn Beckermann, M.D., Samuel Rubinstein, M.D., and Douglas Johnson, M.D., of Vanderbilt University Medical Center, Nashville; Rajat Rai, M.D., Matteo Carlino, M.D., Georgina Long, M.D., and Alexander Menzies, M.D., of the Melanoma Institute Australia and the University of Sydney, Sydney, Australia; John Park, M.D., Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia; Matthew Wongchenko, Isabelle Rooney, M.D., Luna Musib, Ph.D., Nageshwar Budha, Ph.D., Jessie Hsu, Ph.D., Yibing Yan, PH.D., and Edward McKenna, PharmD, of Genentech, San Francisco; Theodore Nowicki, M.D., and Anthoni Ribas, M.D., of the University of California Los Angeles Medical Center; Alexandre Avila, M.D., and Dana Walker, M.D., of Bristol-Myers Squibb, New York; Maneka Puligandla and Sandra Lee, SciD, of Dana-Farber Cancer Institute, Boston; Paul Chapman, M.D., of Memorial Sloan Kettering Cancer Center, New York; Jeffrey Sosman, M.D., of Northwestern University, Chicago; Dirk Schadendorf, M.D., of University Hospital Essen and the German Cancer Consortium, Essen, Germany; Jean-Jacque Grob, M.D., of Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France; Keith Flaherty, M.D., of Massachusetts General Hospital Cancer Center, Boston; and John Kirkwood, M.D., Hillman University of Pittsburgh Medical Center Cancer Center, Pittsburgh.
This research was funded by MD Anderson’s Melanoma Moon Shot™, part of the institution’s Moon Shots Program™, MD Anderson’s Specialized Program in Research Excellence (SPORE) in Melanoma (NIH/NCI P50CA221703), the Dr. Miriam and Sheldon G Adelson Medical Research Foundation, ASCO/CCF Young Investigator and Career Development awards, MD Anderson’s Cancer Center Support Grant from the National Cancer Institute of the National Institutes of Health (P30 CA016672), additional NIH grants (T32 CA009666, P30 CA008748, K23 CA204726 and R01 CA187076-01); the MD Anderson Cancer Center Various Donors Melanoma and Skin Cancers Priority Program Fund; the Miriam and Jim Mulva Research Fund; the McCarthy Skin Cancer Research Fund; the Marit Peterson Fund for Melanoma Research; the University of Sydney Medical Foundation, NHMRC Australian Research Fellowship and a Cancer Institute NSW Fellowship.